Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Adoptive cell transfer of T-cell receptor-engineered lymphocytes: lessons from recent modeling.

Ribas A, Koya RC.

Future Oncol. 2010 Nov;6(11):1671-3. doi: 10.2217/fon.10.137. No abstract available.

2.

[Adoptive immunotherapy for cancer with genetically engineered T cells].

Ikeda H, Okamoto S, Mineno J, Imai N, Ito M, Yasukawa M, Takesako K, Shiku H.

Rinsho Ketsueki. 2010 Nov;51(11):1647-53. Review. Japanese. No abstract available.

PMID:
21157127
3.

Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.

Berry LJ, Moeller M, Darcy PK.

Tissue Antigens. 2009 Oct;74(4):277-89. doi: 10.1111/j.1399-0039.2009.01336.x. Review.

PMID:
19775368
4.

T-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy.

Bobisse S, Zanovello P, Rosato A.

Expert Opin Biol Ther. 2007 Jun;7(6):893-906. Review.

PMID:
17555374
5.

Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.

Wu F, Zhang W, Shao H, Bo H, Shen H, Li J, Liu Y, Wang T, Ma W, Huang S.

Cancer Lett. 2013 Oct 10;339(2):195-207. doi: 10.1016/j.canlet.2013.06.009. Epub 2013 Jun 18.

PMID:
23791878
6.

T-cell engineering for cancer immunotherapy.

Sadelain M.

Cancer J. 2009 Nov-Dec;15(6):451-5. doi: 10.1097/PPO.0b013e3181c51f37. Review.

PMID:
20010162
7.

Prospects for gene-engineered T cell immunotherapy for solid cancers.

Klebanoff CA, Rosenberg SA, Restifo NP.

Nat Med. 2016 Jan;22(1):26-36. doi: 10.1038/nm.4015.

PMID:
26735408
8.

Genetically modulating T-cell function to target cancer.

Merhavi-Shoham E, Haga-Friedman A, Cohen CJ.

Semin Cancer Biol. 2012 Feb;22(1):14-22. doi: 10.1016/j.semcancer.2011.12.006. Epub 2011 Dec 24. Review.

PMID:
22210183
9.

Finding suitable targets is the major obstacle to cancer gene therapy.

Rosenberg SA.

Cancer Gene Ther. 2014 Feb;21(2):45-7. doi: 10.1038/cgt.2014.3. No abstract available.

PMID:
24535159
10.

Antigen choice in adoptive T-cell therapy of cancer.

Offringa R.

Curr Opin Immunol. 2009 Apr;21(2):190-9. doi: 10.1016/j.coi.2009.02.006. Epub 2009 Mar 16. Review.

PMID:
19297140
11.

Adoptive transfer of T-cell immunity.

Kessels HW, Wolkers MC, Schumacher TN.

Trends Immunol. 2002 May;23(5):264-9. Review. No abstract available.

PMID:
12102748
12.

Exploiting T cell receptor genes for cancer immunotherapy.

Xue S, Gillmore R, Downs A, Tsallios A, Holler A, Gao L, Wong V, Morris E, Stauss HJ.

Clin Exp Immunol. 2005 Feb;139(2):167-72. Review.

13.

Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein.

Kalbasi A, Shrimali RK, Chinnasamy D, Rosenberg SA.

J Immunother. 2010 Sep;33(7):672-83. doi: 10.1097/CJI.0b013e3181e475cd.

PMID:
20664359
14.

Moving from tinkering in the garage to assembly line production: the manufacture of genetically modified T cells expressing chimeric antigen receptors (CARs) comes on line.

Cooper LJ.

Cancer Gene Ther. 2015 Mar;22(2):64-6. doi: 10.1038/cgt.2014.70. Epub 2015 Feb 13. Review. No abstract available.

PMID:
25675874
15.

Adoptive immunotherapy for cancer.

Ruella M, Kalos M.

Immunol Rev. 2014 Jan;257(1):14-38. doi: 10.1111/imr.12136. Review.

PMID:
24329787
16.

Adoptive cell therapy: genetic modification to redirect effector cell specificity.

Morgan RA, Dudley ME, Rosenberg SA.

Cancer J. 2010 Jul-Aug;16(4):336-41. doi: 10.1097/PPO.0b013e3181eb3879. Review.

PMID:
20693844
17.

Preclinical development of T cell receptor gene therapy.

Bendle GM, Haanen JB, Schumacher TN.

Curr Opin Immunol. 2009 Apr;21(2):209-14. doi: 10.1016/j.coi.2009.02.007. Epub 2009 Mar 25. Review.

PMID:
19321326
18.

Re-targeting T-cells against cancer by gene-transfer of tumor-reactive receptors.

Marcu-Malina V, van Dorp S, Kuball J.

Expert Opin Biol Ther. 2009 May;9(5):579-91. doi: 10.1517/14712590902887018 . Review.

PMID:
19368527
19.

Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer.

Ochi T, Fujiwara H, Yasukawa M.

Expert Opin Biol Ther. 2011 Jun;11(6):699-713. doi: 10.1517/14712598.2011.566853. Epub 2011 Mar 18. Review.

PMID:
21413911
20.

Prospects and limitations of T cell receptor gene therapy.

Jorritsma A, Schotte R, Coccoris M, de Witte MA, Schumacher TN.

Curr Gene Ther. 2011 Aug;11(4):276-87. Review.

PMID:
21453279

Supplemental Content

Support Center